EssilorLuxottica shares fall 2.5% after HSBC downgrade
The stock loses ground mid-morning, in a CAC 40 trading lower, after a sharp rebound following its quarterly sales. HSBC has also just revised its opinion on the stock.
HSBC moves to hold and cuts its target price to €190
EssilorLuxottica shares fell 2.47% to €179.95, while the CAC 40 dropped 1.03% and the SBF 120 lost as much. The stock is among the largest decliners of the Paris index, in a session marked by the correction of artificial intelligence-related stocks on Wall Street, where the Nasdaq fell 2.49% on Monday.
On the analyst side, HSBC lowered its rating today from buy to hold and reduced its price target from €200 to €190, implying potential of around 5.6% relative to the current share price. The stock nonetheless remains well above its level of a month ago, with a 16.55% gain over the period.
The stock returns to its 200-day moving average
In terms of technical levels, the price has dropped back below its 20-day moving average (MM20) at €183.13 (a gap of 1.74%), while remaining nearly 12% above its 50-day moving average (MM50), at €160.92. It is now in contact with the 200-day moving average (MM200), at €179.47, a gap of only 0.27%, which makes this average the immediate reference following this pullback.
The stock has lost 5.59% over seven days, a decline that erases only part of the rebound seen over the past month. The first nine months of the year, published on October 20, had shown sales up 6.8%, driven by direct-to-consumer sales.
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
SectorDispositifs médicaux et optique›Optique / lunetterie
Context
Period
Period: 9M 2026
Key reported figures
Revenue: 22 304 millions d'euros
Quarterly revenue: 22 304 millions d'euros
Revenue growth: 6,8 %
Opportunities identified
Le portefeuille des solutions de gestion de la myopie a progressé de +24 % sur les neuf premiers mois
Les activités traditionnelles (Eyecare & Medtech) ont progressé à un rythme supérieur à +6 %, tant au T3 que sur les neuf premiers mois
Segment Direct to Consumer en hausse de +10,6 % au T3, ventes à magasins comparables à +6,8 %
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.